Reader TTS

ABSTRACT Intravenous ketamine is posited to rapidly reverse depression by rapidly enhancing neuroplasticity. In human patients, we quantified gray matter microstructural changes on a rapid

(24-h) timescale within key regions where neuroplasticity enhancements post-ketamine have been implicated in animal models. In this study, 98 unipolar depressed adults who failed at least

one antidepressant medication were randomized 2:1 to a single infusion of intravenous ketamine (0.5 mg/kg) or vehicle (saline) and completed diffusion tensor imaging (DTI) assessments at

pre-infusion baseline and 24-h post-infusion. DTI mean diffusivity (DTI-MD), a putative marker of microstructural neuroplasticity in gray matter, was calculated for 7 regions of interest

(left and right BA10, amygdala, and hippocampus; and ventral Anterior Cingulate Cortex) and compared to clinical response measured with the Montgomery-Asberg Depression Rating Scale (MADRS)

and the Quick Inventory of Depressive Symptoms-Self-Report (QIDS-SR). Individual differences in DTI-MD change (greater decrease from baseline to 24-h post-infusion, indicative of more

neuroplasticity enhancement) were associated with larger improvements in depression scores across several regions. In the left BA10 and left amygdala, these relationships were driven

primarily by the ketamine group (group * DTI-MD interaction effects: _p_ = 0.016–0.082). In the right BA10, these associations generalized to both infusion arms (_p_ = 0.007). In the left

and right hippocampus, on the MADRS only, interaction effects were observed in the opposite direction, such that DTI-MD change was inversely associated with depression change in the ketamine

arm specifically (group * DTI-MD interaction effects: _p_ = 0.032–0.06). The acute effects of ketamine on depression may be mediated, in part, by acute changes in neuroplasticity

quantifiable with DTI. SIMILAR CONTENT BEING VIEWED BY OTHERS STUDYING PRE-TREATMENT AND KETAMINE-INDUCED CHANGES IN WHITE MATTER MICROSTRUCTURE IN THE CONTEXT OF KETAMINE’S ANTIDEPRESSANT

EFFECTS Article Open access 15 December 2020 VOLUMETRIC CHANGES IN SUBCORTICAL STRUCTURES FOLLOWING REPEATED KETAMINE TREATMENT IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A LONGITUDINAL

ANALYSIS Article Open access 03 August 2020 HIPPOCAMPAL VOLUME CHANGES AFTER (_R,S_)-KETAMINE ADMINISTRATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND HEALTHY VOLUNTEERS Article Open

access 24 February 2024 INTRODUCTION Major depressive disorder is the leading cause of disability adjusted life years (DALYs) in the USA and represents an enormous public health burden [1].

Deficits in neuroplasticity and corresponding deficits in the ability to respond adaptively to the environment are seen in both depressed human subjects and in rodent models of

depression-like behavior, and therefore may be a core mechanism underlying the disorder [2]. A diversity of structural and functional deficits in neuroplasticity underlie depression-like

behavioral states seen in rodents following stress exposure (e.g., anhedonia-like behavior, tested via the sucrose preference test; anxiety-like behavior, indexed by the novelty-suppressed

feeding test; and despair-like behavior, observed during the forced swim test) [3]. These neuroplasticity deficits include decreased long-term potentiation and/or increased long-term

depression, decreased synaptic protein expression, impaired BDNF and mTOR signaling, decreased synaptogenesis/atrophy of existing synapses, and decreased neurogenesis/atrophy of neurons,

ultimately resulting in dysfunction of corticolimbic circuits and expression of maladaptive behavioral strategies [2, 4,5,6,7,8]. Effective antidepressant therapies have been shown to

reverse many of these deficits, further emphasizing the relevance of these studies to depression and providing some of the strongest evidence to date that impairments in neuroplasticity may

be a core mechanism underlying depression [9,10,11,12]. While functional neuroplasticity cannot be directly tested in the living human brain, post-mortem studies of depression show

reductions in markers of neuroplasticity, including reduced BDNF and decreased synapses and synapse-related gene expression [13, 14]. Neuroimaging studies in depressed subjects reveal

hypofunction and gray matter volume loss in key corticolimbic structures including the PFC and hippocampus, as well as decreased functional integration across these regions and their

associated networks. These neural network alterations are hypothesized to result in deficits in flexible cognition and affective processing that manifest in depressed patients as rigid,

maladaptive behavioral responses [15, 16]. Recent evidence has shown that ketamine, a dissociative anesthetic, has rapid and robust antidepressant effects, including in treatment-resistant

patients for whom other therapies have been ineffective [17,18,19,20,21,22]. These results have been widely replicated, but the exact mechanisms by which ketamine reduces depressive

symptomology remain unknown. Results in rodent models indicate that a single dose of ketamine induces robust markers of neuroplasticity in depression-relevant brain regions, including

increased BDNF release and the stimulation of mTOR signaling in the PFC [23, 24]. In addition, ketamine induces an increase in synapse number and function in the PFC, reversing the loss of

specific synapses by stress, an effect that seems necessary for the persistence of its antidepressant-like behavioral effects [12, 24]. In humans, ketamine also alters neural response to

emotional stimuli [25] and EEG gamma power [26,27,28,29], a putative marker of activity-dependent plasticity. To our knowledge, no one has specifically linked microstructural neuroplasticity

induced by ketamine—akin to the synaptogenesis in the PFC observed in animal models—to its antidepressant effects in humans. While real-time neuroplasticity cannot be directly assessed in

the intact human brain, recent advances in neuroimaging have provided evidence that structural remodeling of the human brain can be measured within hours of its occurrence. Several studies

have used diffusion tensor imaging (DTI), an MRI-based framework, as an indirect marker of neuroplasticity [30,31,32,33]. Mean diffusivity (MD) within gray matter regions, an index derived

from DTI, is a measure of water diffusion and therefore tissue density. The generation of new synapses, an important common final pathway of neuroplasticity, results in a decrease in MD, as

these novel synapses restrict the flow of water within gray matter [30]. Studies have shown decreases in MD within memory-related brain regions within 2 h of training tasks [30, 31, 33].

This finding was replicated in rodents, and the decrease in DTI-MD was shown to correlate with traditional markers of cellular and molecular neuroplasticity, including increased number of

synaptic vesicles, astrocyte activation, and increased expression of synaptic-related proteins, including BDNF [30]. Collectively, these findings in animals and humans specifically tie acute

DTI-MD changes to neuroplasticity processes including those involved in synaptogenesis—a prominent mechanism implicated in ketamine’s mechanism of antidepressant action [12, 24]. In the

current study, we measured DTI-MD in depression-relevant brain regions (BA10, amygdala, hippocampus, and ventral ACC) before and 24-h following the administration of IV ketamine (0.5 mg/kg)

or saline vehicle in depressed human subjects, and related individual differences in these acute neuroplasticity markers to the degree of clinical response 24-h post-infusion. We

hypothesized that individual differences in region-specific changes in DTI-MD would predict the response to treatment primarily in patients receiving ketamine, with larger clinical

improvements following ketamine tracking with greater degrees of structural change, putatively reflecting neuroplasticity enhancement. METHODS This study included secondary analyses of data

generated from clinical trial NCT03237286. Study design and primary clinical outcomes have been detailed previously [34]. In the full trial, 154 adult subjects (age 18–60) with moderate to

severe depression [Montgomery-Asberg Depression Rating Scale (MADRS [35]) score ≥25] and at least one adequate, failed trial of an FDA-approved antidepressant medication in the current

depressive episode (assessed via Antidepressant Treatment Response Questionnaire; ATRQ [36]), were enrolled and randomized to receive either ketamine or vehicle in a 2:1 ratio. An

experienced, Master’s-level clinical rater (CRS) administered the MADRS (the primary clinician-rated outcome used for the clinical trial) prior to, and 24 h post-infusion to assess overall

depression severity and change following intervention. Similarly, patients self-reported depressive symptoms before and 24-h following ketamine using the Quick Inventory of Depressive

Symptoms (QIDS-SR) [37, 38], the primary self-report outcome. A subset of these subjects (31 vehicle, 67 ketamine) had usable DTI neuroimaging data collected prior to and 24-h post-infusion

and are included in the current analyses. Subjects received either ketamine (0.5 mg/kg) or vehicle (50 ml 0.9% NaCl) infused over 40-min, as done previously [39,40,41]Footnote 1. All

infusions were administered by blinded, licensed nurses in a medical hospital setting with linked ACLS-certified team, blinded study physician (RHH) oversight, and safety/adverse event

monitoring sustained for 4-h post-infusion. Current medications and doses were obtained from subjects via the community treatment form or patient interview with study staff. When there was a

discrepancy between these two sources or missing information that could not be resolved via subject follow-up, collateral was obtained from the patient’s electronic medical record.

Medication burden was calculated based on the Anti-Depressant Treatment History Form (ATHF) [42,43,44]. The study was performed at the University of Pittsburgh and approved by the Internal

Review Board of the University of Pittsburgh. All participants provided informed consent prior to any study procedure. See Table 1 for descriptive patient characteristics. NEUROIMAGING

ACQUISITION All neuroimaging data were acquired using a 3T Siemens Prisma and a Siemens 64-channel head coil at the University of Pittsburgh. Diffusion-weighted structural images were

acquired using the multi-band sequences (version R016A) provided by the University of Minnesota Center for Magnetic Resonance Research (https://www.cmrr.umn.edu/multi band/).

Diffusion-weighted images were collected as oblique-axial scans aligned with the anterior commissure–posterior commissure (AC–PC) line at midline with the monopolar cmrr_mbep2d_diff sequence

(http://www.cmrr.umn.edu/multi band) in 72 slices (an ascending interleaved acquisition with 2.0-mm-thick slices and no inter-slice gap). The matrix was 104 × 104 and FOV was 208 mm,

resulting in 2.0-mm isotropic voxels (TR = 2443 ms, TE = 88.0 ms, multi-band acceleration factor = 4, number of diffusion encoded directions = 30, diffusion _b_ value = 1000 s/mm2, number of

non-diffusion-encoded images = 4, bandwidth = 2004 Hz/pixel, partial Fourier factor of 7/8). The 30 diffusion encoding vectors were taken from a standard Siemens gradient table. Two sets of

these images with opposite phase encoding directions (anterior -> posterior and posterior -> anterior) were collected for each participant in each scanning session (baseline and

24-h). A high-resolution structural scan was also acquired at the baseline scan session (axial MPRAGE: TR = 2400; TE = 2.22; 208 slices; flip angle = 8°; 0.8 mm isotropic voxels).

NEUROIMAGING PROCESSING Images were preprocessed in FSL v. 5.0 (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki) following a standard DTI pipeline [33] that included the following steps: correction

of geometric distortions (topup), motion (mcflirt), and eddy currents (eddy); linear co-registration of baseline and 24-h data (flirt); non-linear warping to MNI space (fsl_reg to

“FMRIB58_FA_1mm” template); and fitting a weighted-least squared diffusion tensor model (dtifit) to produce voxel-wise maps of mean diffusivity at each scan session. A DTI-MD change score

(∆-MD = MD pre-infusion – MD at 24 h) was then calculated for each of the following ROIs: left and right BA10, left and right amygdala, left and right hippocampus, and ventral anterior

cingulate cortex (vACC; encompassing subgenual and perigenual ACC). These specific regions were selected for analysis based on a priori hypotheses about the role of these regions in both the

antidepressant response to ketamine (which has particularly implicated hippocampus and medial PFC areas, including bilateral BA10 and vACC; see [2]) and in depression pathophysiology at

large, which additionally establishes a prominent role for the amygdala in depressed patients’ altered patterns of affective processing (reviewed in [2]). Anatomical masks for each ROI were

constructed using the MNI atlas and applied to extract the MD score for each participant as an average of all voxels within each ROI. A higher ∆-MD score corresponds to lower mean

diffusivity following the infusion, and putatively greater plasticity/synaptogenesis [30]. A Winsorizing procedure was used to rescale extreme ∆-MD values prior to analysis, as described

previously [45]. All statistics were run using IBM SPSS Statistics (version 28.0.1.0). To test for the effect of group (ketamine vs. vehicle) on ∆ depression scores and ∆-MD, two-tailed

independent sample _t_-tests were performed. Multiple linear regression was performed to predict the improvement in depression (measured as change in MADRS and QIDS-SR scores) from ∆-MD and

group (ketamine vs. vehicle), as well as their interaction—enabling formal assessment of any distinct relationships between neuroplasticity and clinical improvement that were evident in the

ketamine vs. vehicle arms. Parallel, exploratory analyses of three additional outcome measures (measuring anxiety, positive affect, and dissociative side effects) are presented in the online

Supplement. RESULTS MAIN EFFECTS OF TREATMENT GROUP In the full clinical trial sample, ketamine significantly improved MADRS (_t_(150) = −4.55, _p_ < 0.001) and QIDS (_t_(148) = −2.60,

_p_ = 0.010) scores 24-h post-infusion. In the subset of patients with DTI neuroimaging data, ketamine significantly improved MADRS scores 24-h post-infusion (_t_(96) = −3.01, _p_ = 0.003),

while there was no significant effect of ketamine on change in QIDS-SR score 24-h post-infusion in this subset of patients (_t_(95) = −1.10, _p_ = 0.28). Ketamine had no significant main

effect on either raw or Winsorized ∆-MD values in any of the regions investigated. MODERATION OF CLINICAL OUTCOMES BY RAPID CHANGE IN MD Linear regression was performed to predict the

improvement in QIDS and MADRS from ∆-MD values, group (ketamine vs. vehicle), and their interaction. Results for all regions are shown in Table 2. L BA10 For QIDS scores, there was a

significant ∆-MD * group interaction effect, such that decreased MD scores (i.e., putative neuroplasticity increase) predicted greater improvement in QIDS scores in the ketamine group

specifically (_β_ = 0.386, _t_(96) = 2.143, _p_ = 0.035; Fig. 1A). For MADRS scores, there was a significant main effect of group (_β_ = 0.314, _t_(96) = 3.207, _p_ = 0.002) and a trend for

a ∆-MD * group interaction effect (_β_ = 0.308, _t_(96) = 1.760, _p_ = 0.082; Fig. 1B). Greater improvement in MADRS scores was associated with a reduction in MD, and this relationship was

particularly evident in the ketamine group. R BA10 There was a significant main effect of ∆-MD on QIDS (∆-MD: _β_ = 0.275, _t_(96) = 2.771, _p_ = 0.007; Fig. 1C) and a significant main

effect of both ∆-MD and group on MADRS scores (∆-MD: _β_ = 0.196, _t_(96) = 2.019, _p_ = 0.046; group: _β_ = 0.268, _t_(96) = 2.763 _p_ = 0.007; Fig. 1D), such that reduced MD predicted

greater improvement in depression score (independent of group). There was no significant ∆-MD * group interaction effect in this region for either QIDS or MADRS (_p_ ≥ 0.195). L AMYGDALA

There was a significant ∆-MD * group interaction effect on both QIDS (_β_ = 0.477, _t_(96) = 2.446, _p_ = 0.016; Fig. 1E) and MADRS (_β_ = 0.414, _t_(96) = 2.238, _p_ = 0.028; Fig. 1F) such

that decreases in MD predicted greater improvement in depression in the ketamine group specifically. L HIPPOCAMPUS For the MADRS only, there was a significant ∆-MD * group interaction effect

(_β_ = −0.337, _t_(96) = −2.178, _p_ = 0.032; Fig. 2A). The directionality of these results is opposite to those in left BA10 and left amygdala above, such that increased MD predicted

improved MADRS score in the ketamine group. There were no significant main or interaction effects predicting improvement in QIDS score (_p_ > 0.05). R HIPPOCAMPUS For the MADRS only,

there were significant main effects of group (_β_ = 0.343, _t_(96) = 3.420, _p_ = 0.001) and a trend-level ∆-MD * group interaction in right hippocampus (_β_ = −0.303, _t_(96) = −1.902, _p_ 

= 0.060; Fig. 2B). Like in the left hippocampus, increased MD in the right hippocampus predicted improved MADRS score following ketamine. There were no significant main or interaction

effects predicting improvement in QIDS score (_p_ > 0.05). OTHER REGIONS EXAMINED AND SENSITIVITY ANALYSES There were no significant main or interaction effects in the right amygdala or

the vACC. Sensitivity analyses were performed to assess robustness of interaction effect findings when including the following covariates: baseline DTI-MD score, severity of treatment

resistance [moderate (<3 failed adequate trials) vs. severe], and use of concurrent psychotropic medications (see Table 2). Inclusion of each covariate into our statistical models had

minimal impact on the pattern and statistical significance of the findings described above. DISCUSSION In the present study, we found an association between change in DTI-MD (∆-MD), a

putative marker of neuroplasticity, and treatment response to ketamine in a sample of patients with depression. Reductions in MD scores in left BA10 and left amygdala, representing putative

increased plasticity in these regions, predicted greater improvement in depression scores specifically in patients receiving ketamine. In right BA10, decreased MD scores predicted greater

improvement in depression scores, independent of group (as reflected in the lack of a significant group * ∆-MD interaction effect). In both right and left hippocampus, the results were

paradoxically in the opposite direction, with higher ∆-MD scores predicting greater improvement in clinician-rated depression scores in subjects receiving ketamine. However, there was no

similar interaction between ∆-MD and group in predicting self-reported depression scores in either left or right hippocampus. Lastly, we found no significant effect of ∆-MD on depression

scores in vACC or right amygdala. These findings were not appreciably changed in sensitivity analyses that included covariates in the statistical models, including concomitant psychiatric

medication burden, level of treatment resistance, and baseline DTI-MD values (Table 2). To our knowledge, this is the first placebo-controlled human study to investigate the association

between a structural marker of acute neuroplasticity in depression-relevant brain regions and treatment response to ketamine, providing a first attempt to translate animal neuroscience

findings, which have widely implicated synaptogenic mechanisms of action, back to the clinic. The regions in which increased plasticity predicted change in depression scores are right and

left BA10 and left amygdala. Activity in these regions has been shown to be altered in depressed subjects, with studies of BA10 (and nearby related PFC regions) showing hyperactivation to

reward-related cues and hypoactivation to negative affective cues (e.g., negatively valanced faces) in depressed subjects relative to controls [46]. Furthermore, a large body of literature

in depressed subjects shows hyperactivation of the amygdala in response to negative affective cues and hypoactivation in response to positive affective cues (e.g., positively valanced faces)

relative to controls [47]. Antidepressants may also change activity in these regions, with a meta-analysis showing that the neural biases in emotional processing in depressed subjects in

the PFC and amygdala were normalized following the administration of an SSRI [48]. Some more recent evidence indicates that this may be true for treatment with ketamine as well, with

decreased amygdala activity in response to emotionally salient stimuli being perhaps the most well-replicated finding in the ketamine neuroimaging literature [49,50,51,52]. Many previous

neuroimaging studies of response to ketamine have also shown changes in functional connectivity across brain networks, and while this literature is expansive and varied, studies have

consistently implicated functional connectivity involving BA10 and related PFC regions and the amygdala in the antidepressant response to ketamine [51, 53,54,55,56]. Interestingly, the

laterality of regions involved in ketamine response in human neuroimaging research varies from study-to-study, with the exception of the left amygdala, which, as in our current study, is

consistently implicated more commonly than the right amygdala [50]. The structural mechanisms that underlie the functional changes in BA10 and left amygdala described above are unknown, but

likely involve remodeling at the circuit, cellular, and/or synaptic level. This type of remodeling alters brain microstructure, leading to a change in the diffusion properties of water

within this region (i.e., diffusion is restricted), resulting in a decrease in MD that reflects increased neuroplasticity [30,31,32]. The changes we observed in BA10 and left amygdala

following ketamine administration could represent a structural correlate of the antidepressant behavioral effect of the drug. Ketamine rapidly alters neural and behavioral responses to

incoming stimuli, with changes in how brain regions respond to emotional stimuli and accompanying changes in behavioral output [29, 49, 50, 52]. One way by which this could happen is the

rearrangement of multi-synaptic connections between sensory input and behavioral output, reflected in this study as a decrease in MD. The amygdala in particular plays an important role in

responding to emotional stimuli and regulating behavioral output. Structural plasticity in this region might thus be readily leveraged to reduce the salience of negative stimuli and increase

the salience of positive emotional stimuli. Through further testing of this hypothesis, the molecular effects of ketamine might be traced to its neural and behavioral effects in human

patients. While in left BA10 there was a significant ∆-MD × group interaction effect, there was no similar interaction effect in the right BA10. This could indicate that plasticity in this

region may play a larger role in the non-specific antidepressant effects that are common between the ketamine and placebo control groups, such as those associated with the infusion/research

protocol, including the formation of therapeutic relationships, being in a therapeutic environment, positive feelings of helping others by contributing to research, and expectation of

improvement. In contrast to the results seen in BA10 and left amygdala, which conformed to expectations based on the animal literature, in both the left and right hippocampus there was a

significant effect in the opposite direction, with increased MD being associated with improved clinician-rated depression scores in the ketamine group. Unlike the majority of other findings

we report, which were largely robust across both clinician- and self-rated depression symptoms (e.g., Fig. 1 and Table 2), this pattern did not generalize to the QIDS, and may therefore be

less reliable. While a decrease in MD is assumed to represent increased plasticity, with some mechanistic data to support this [30], the interpretation of increased MD is less

straightforward. Increased MD could represent an inverse mechanism of the decrease in MD, i.e., increased MD = decreased plasticity. If this is the case, it may be that ketamine causes

selective pruning of hippocampal synapses (e.g., those associated with maladaptive behavioral responses). However, it seems unlikely that an overall decrease in plasticity of the hippocampus

would be associated with improved depression scores following ketamine, especially in a sample of depressed subjects where low levels of hippocampal plasticity and structural integrity are

posited to occur at baseline. Other interpretations are potentially more likely and are not mutually exclusive. Increased MD has been associated with specific behavioral states, including

higher empathizing and cooperativeness [57], which might be more likely to occur in patients with more improved depression scores. It has also previously been reported that MD increases in

response to increases in cerebral blood flow (CBF) [58,59,60]. There is some evidence that improvement in particular symptom domains, namely anhedonia, is positively correlated with regional

glucose metabolic rates, and we cannot rule out CBF increases being similarly associated with antidepressant response as well as increased MD. Other causes of increased MD, such as changes

in dopamine or iron content of tissue, atrophy, or inflammation are possible, but less likely to be occurring in the hippocampus 24-h following the administration of ketamine [30, 57, 58,

61]. Finally, we did not observe any relationships between clinical outcomes and ∆-MD in two other regions included in analyses: right amygdala and vACC. Relative to the other regions under

examination, the specific neural processes captured via DTI-MD within these two regions may play a less foundational role in ketamine’s rapid antidepressant effects; although we cannot rule

out other possible explanations, such as measurement error, insufficient sample size, and other contributors to Type II error. Our data have clinical implications for the use of ketamine for

depression. The plasticity induced by ketamine seems to persist, at least out to 24-h post-infusion, and potentially well beyond this. We can take advantage of this period of increased

plasticity to augment the antidepressant effects of ketamine by combining it with other therapies, such as cognitive training. Indeed, in the primary outcome for this clinical trial, we

previously reported that Automated Self-Association Training—a novel, low-cost, brief, computer-based intervention—extended the rapid antidepressant effect of a single ketamine infusion for

at least 30 days [34]. In addition to this potential for combinatorial, synergistic treatments, this study also points to the potential importance of the environment following treatment. If

the brain is in a plastic state following ketamine, then the potential impact of the environment over the next 24+ h could be outsized, with a therapeutic environment potentially

strengthening the effects of ketamine and a stressful environment potentially weakening them. There are some limitations to the current study. Our measure of acute neuroplasticity, ∆-MD, is

by necessity an indirect measure. While the previous studies using this metric as a measure of acute plasticity were investigating changes in hippocampal MD following learning, we are using

it as a proxy for neuroplasticity in the context of treatment response for psychiatric disorders. Other factors that affect the diffusion of water, such as inflammation, could serve as

confounds for our interpretation. The study was also limited by sample size, with 31 vehicle and 67 ketamine subjects, which is a subset of the whole clinical trial, and was likely

underpowered to detect some interaction effects suggested by visual plots (Fig. 1), as well as a main effect of ketamine on QIDS scores, an effect that was present in the whole sample. The

difference in sample sizes also makes us better powered to find significant post hoc correlations between changes in depression score and ∆-MD in specific regions in the ketamine group

relative to the saline group. In an effort to balance between Type I and Type II error risk, we selected a constrained set of 7 regions a priori and did not adjust for multiple comparisons

within this confined set. Our study also did not include individuals without depression, precluding the ability to assess for baseline group differences in DTI-MD as well as normalization of

any such differences following ketamine. Changes in MD in several regions significantly predicted improvement in depression scores, however the effect sizes were relatively small, with _R_2

values between 0.05 and 0.18. Lastly, there was no main effect of ketamine on ∆-MD, as we might predict if it were the sole mediator of treatment response, indicating that numerous other

factors are likely involved in the antidepressant effects of ketamine among human patients. Such factors could include additional neuroplasticity mechanisms, such as the impact of ketamine

on white matter microstructure and tractography [62, 63] which was not assessed in the current study due to scanner sequence timing constraints and lack of a priori hypotheses regarding

white matter effects; as well as a wide range of factors beyond neuroplasticity per se. CONCLUSION In the past two decades, ketamine has emerged as one of the most promising pharmacological

treatments for depression since selective serotonin re-uptake inhibitors (SSRIs) became available. While the exact mechanism is unknown, it has been hypothesized that ketamine’s

antidepressant effects are at least in part mediated by increases in neuroplasticity broadly, and by synaptogenic actions specifically. We found that a proxy for structural neuroplasticity

was associated with treatment response to ketamine in a subset of the depression-relevant brain regions we examined. These results have important implications for the development of

synergistic therapies and for understanding the neurobiological mechanisms by which ketamine exerts rapid antidepressant actions in depressed patients. NOTES * _N_ = 28 patients were

enrolled prior to adding the DTI sequence to the MRI protocol; _N_ = 23 had unusable DTI data due to a scanner acquisition error at one or more timepoints; _N_ = 3 did not complete DTI

sequence due to scanner time constraints; _N_ = 2 patients did not return to complete 24-h MRI scan. REFERENCES * GBD 2019 Mental Disorders Collaborators. Global, regional, and national

burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet Psychiatry. 2022;9:137–50. Article 

PubMed Central  Google Scholar  * Price RB, Duman R. Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model. Mol Psychiatry 2020;25:530–43. Article 

PubMed  Google Scholar  * Wang Q, Timberlake MA, Prall K, Dwivedi Y. The recent progress in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2017;77:99–109. Article 

PubMed  PubMed Central  Google Scholar  * Liu B, Liu J, Wang M, Zhang Y, Li L. From serotonin to neuroplasticity: evolvement of theories for major depressive disorder. Front Cell Neurosci.

2017;11:305. Article  CAS  PubMed  PubMed Central  Google Scholar  * Castrén E, Monteggia LM. Brain-derived neurotrophic factor signaling in depression and antidepressant action. Biol

Psychiatry. 2021;90:128–36. Article  PubMed  Google Scholar  * De Gregorio D, Aguilar-Valles A, Preller KH, Heifets BD, Hibicke M, Mitchell J, et al. Hallucinogens in mental health:

preclinical and clinical studies on lsd, psilocybin, mdma, and ketamine. J Neurosci. 2021;41:891–900. Article  PubMed  PubMed Central  Google Scholar  * Aleksandrova LR, Wang YT, Phillips

AG. Evaluation of the wistar-kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response. Neurosci Biobehav Rev. 2019;105:1–23. Article  CAS 

PubMed  Google Scholar  * Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med.

2016;22:238–49. Article  CAS  PubMed  PubMed Central  Google Scholar  * Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat

hippocampus. J Neurosci. 2000;20:9104–10. Article  CAS  PubMed  PubMed Central  Google Scholar  * Castrén E. Is mood chemistry? Nat Rev Neurosci. 2005;6:241–46. Article  PubMed  Google

Scholar  * Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science.

2003;301:805–9. Article  CAS  PubMed  Google Scholar  * Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, et al. Sustained rescue of prefrontal circuit dysfunction by

antidepressant-induced spine formation. Science. 2019;364:eaat8078. Article  CAS  PubMed  PubMed Central  Google Scholar  * Kang HJ, Voleti B, Hajszan T, Rajkowska G, Stockmeier CA,

Licznerski P, et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med. 2012;18:1413–17. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008;64:527–32.

Article  CAS  PubMed  PubMed Central  Google Scholar  * Disner SG, Beevers CG, Haigh EAP, Beck AT. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci. 2011;12:467–77.

Article  CAS  PubMed  Google Scholar  * Siegle GJ, Thompson W, Carter CS, Steinhauer SR, Thase ME. Increased amygdala and decreased dorsolateral prefrontal bold responses in unipolar

depression: related and independent features. Biol Psychiatry. 2007;61:198–209. Article  PubMed  Google Scholar  * Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting

antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med. 2015;66:509–23. Article  CAS  PubMed  Google Scholar  * Xu Y, Hackett M, Carter G, Loo C,

Gálvez V, Glozier N, et al. Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol.

2016;19:pyv124. Article  PubMed  Google Scholar  * Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant

major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134–42. Article  PubMed  PubMed Central  Google Scholar  * McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham

LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med.

2015;45:693–704. Article  CAS  PubMed  Google Scholar  * Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions,

and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol. 2014;4:75–99. Article  CAS  PubMed  PubMed Central  Google Scholar  * Berman RM, Cappiello A, Anand A, Oren

DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–54. Article  CAS  PubMed  Google Scholar  * Li N, Lee B, Liu R-J,

Banasr M, Dwyer JM, Iwata M, et al. MTOR-dependent synapse formation underlies the rapid antidepressant effects of nmda antagonists. Science. 2010;329:959–64. Article  CAS  PubMed  PubMed

Central  Google Scholar  * Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: gaba and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron.

2019;102:75–90. Article  CAS  PubMed  PubMed Central  Google Scholar  * Murrough JW, Collins KA, Fields J, DeWilde KE, Phillips ML, Mathew SJ, et al. Regulation of neural responses to

emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Transl Psychiatry. 2015;5:e509. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Rivolta D, Heidegger T, Scheller B, Sauer A, Schaum M, Birkner K, et al. Ketamine dysregulates the amplitude and connectivity of high-frequency oscillations in cortical-subcortical networks

in humans: evidence from resting-state magnetoencephalography-recordings. Schizophr Bull. 2015;41:1105–14. Article  PubMed  PubMed Central  Google Scholar  * Shaw AD, Saxena N, E Jackson L,

Hall JE, Singh KD, Muthukumaraswamy SD. Ketamine amplifies induced gamma frequency oscillations in the human cerebral cortex. Eur Neuropsychopharmacol. 2015;25:1136–46. Article  CAS  PubMed

  Google Scholar  * Farmer CA, Gilbert JR, Moaddel R, George J, Adeojo L, Lovett J, et al. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled,

crossover trial for treatment-resistant major depression. Neuropsychopharmacology. 2020;45:1398–404. Article  CAS  PubMed  PubMed Central  Google Scholar  * Nugent AC, Ballard ED, Gould TD,

Park LT, Moaddel R, Brutsche NE, et al. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry. 2019;24:1040–52. Article  CAS 

PubMed  Google Scholar  * Sagi Y, Tavor I, Hofstetter S, Tzur-Moryosef S, Blumenfeld-Katzir T, Assaf Y. Learning in the fast lane: new insights into neuroplasticity. Neuron.

2012;73:1195–203. Article  CAS  PubMed  Google Scholar  * Tavor I, Botvinik-Nezer R, Bernstein-Eliav M, Tsarfaty G, Assaf Y. Short-term plasticity following motor sequence learning revealed

by diffusion magnetic resonance imaging. Hum Brain Mapp. 2020;41:442–52. Article  PubMed  Google Scholar  * Just MA, Keller TA. Converging measures of neural change at the microstructural,

informational, and cortical network levels in the hippocampus during the learning of the structure of organic compounds. Brain Struct Funct. 2019;224:1345–57. Article  CAS  PubMed  Google

Scholar  * Keller TA, Just MA. Structural and functional neuroplasticity in human learning of spatial routes. Neuroimage. 2016;125:256–66. Article  PubMed  Google Scholar  * Price RB, Spotts

C, Panny B, Griffo A, Degutis M, Cruz N, et al. A novel, brief, fully automated intervention extends the antidepressanteffect of a single ketamine infusion: a randomized clinical trial. Am

J Psychiatry. 2022;179:959–68. Article  PubMed  Google Scholar  * Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–89.

Article  CAS  PubMed  Google Scholar  * Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M. RESEARCH: validation of the massachusetts general hospital antidepressant treatment history

questionnaire (ATRQ). CNS Neurosci Ther. 2010;16:322–25. Article  PubMed  PubMed Central  Google Scholar  * Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-item

quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol

Psychiatry. 2003;54:573–83. Article  PubMed  Google Scholar  * Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. The inventory of depressive symptomatology, clinician

rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood

disorders: a psychometric evaluation. Psychol Med. 2004;34:73–82. Article  CAS  PubMed  Google Scholar  * Murrough JW, Soleimani L, DeWilde KE, Collins KA, Lapidus KA, Iacoviello BM, et al.

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45:3571–80. Article  CAS  PubMed  Google Scholar  * Price RB, Iosifescu DV, Murrough JW,

Chang LC, Al Jurdi RK, Iqbal SZ, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety.

2014;31:335–43. Article  CAS  PubMed  PubMed Central  Google Scholar  * Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of

suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66:522–26. Article  CAS  PubMed  PubMed Central  Google Scholar  * Sackeim HA, Aaronson ST, Bunker MT, Conway CR,

Demitrack MA, George MS, et al. The assessment of resistance to antidepressant treatment: rationale for the antidepressant treatment history form: short form (ATHF-SF). J Psychiatr Res.

2019;113:125–36. Article  PubMed  Google Scholar  * Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62:10–17. CAS  PubMed  Google Scholar  *

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a star*d

report. Am J Psychiatry. 2006;163:1905–17. Article  PubMed  Google Scholar  * Price RB, Kuckertz JM, Siegle GJ, Ladouceur CD, Silk JS, Ryan ND, et al. Empirical recommendations for improving

the stability of the dot-probe task in clinical research. Psychol Assess. 2015;27:365–76. Article  PubMed  Google Scholar  * Pizzagalli DA, Roberts AC. Prefrontal cortex and depression.

Neuropsychopharmacology. 2022;47:225–46. Article  PubMed  Google Scholar  * Stuhrmann A, Suslow T, Dannlowski U. Facial emotion processing in major depression: a systematic review of

neuroimaging findings. Biol Mood Anxiety Disord. 2011;1:10. Article  PubMed  PubMed Central  Google Scholar  * Ma Y. Neuropsychological mechanism underlying antidepressant effect: a

systematic meta-analysis. Mol Psychiatry. 2015;20:311–19. Article  CAS  PubMed  Google Scholar  * Loureiro JRA, Leaver A, Vasavada M, Sahib AK, Kubicki A, Joshi S, et al. Modulation of

amygdala reactivity following rapidly acting interventions for major depression. Hum Brain Mapp. 2020;41:1699–710. Article  PubMed  PubMed Central  Google Scholar  * Alario AA, Niciu MJ.

Biomarkers of ketamine’s antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology. Chronic Stress. 2021;5:24705470211014210. Article  PubMed  PubMed

Central  Google Scholar  * Nugent AC, Farmer C, Evans JW, Snider SL, Banerjee D, Zarate CA. Multimodal imaging reveals a complex pattern of dysfunction in corticolimbic pathways in major

depressive disorder. Hum Brain Mapp. 2019;40:3940–50. PubMed  PubMed Central  Google Scholar  * Reed JL, Nugent AC, Furey ML, Szczepanik JE, Evans JW, Zarate CA. Ketamine normalizes brain

activity during emotionally valenced attentional processing in depression. Neuroimage Clin. 2018;20:92–101. Article  PubMed  PubMed Central  Google Scholar  * Evans JW, Szczepanik J,

Brutsché N, Park LT, Nugent AC, Zarate CA. Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration. Biol Psychiatry. 2018;84:582–90.

Article  CAS  PubMed  PubMed Central  Google Scholar  * Nakamura T, Tomita M, Horikawa N, Ishibashi M, Uematsu K, Hiraki T, et al. Functional connectivity between the amygdala and subgenual

cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment-resistant depression. Neuropsychopharmacol Rep. 2021;41:168–78. Article  CAS  PubMed  PubMed

Central  Google Scholar  * Rivas-Grajales AM, Salas R, Robinson ME, Qi K, Murrough JW, Mathew SJ. Habenula connectivity and intravenous ketamine in treatment-resistant depression. Int J

Neuropsychopharmacol. 2021;24:383–91. Article  CAS  PubMed  Google Scholar  * Chen M-H, Lin W-C, Tu P-C, Li C-T, Bai Y-M, Tsai S-J, et al. Antidepressant and antisuicidal effects of ketamine

on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: a double-blind, placebo-controlled, randomized, longitudinal resting fMRI study. J

Affect Disord. 2019;259:15–20. Article  CAS  PubMed  Google Scholar  * Takeuchi H, Taki Y, Nouchi R, Yokoyama R, Kotozaki Y, Nakagawa S, et al. Empathizing associates with mean diffusivity.

Sci Rep. 2019;9:8856. Article  PubMed  PubMed Central  Google Scholar  * Takeuchi H, Taki Y, Nouchi R, Hashizume H, Sekiguchi A, Kotozaki Y, et al. Working memory training impacts the mean

diffusivity in the dopaminergic system. Brain Struct Funct. 2015;220:3101–11. Article  CAS  PubMed  Google Scholar  * Song AW, Woldorff MG, Gangstead S, Mangun GR, McCarthy G. Enhanced

spatial localization of neuronal activation using simultaneous apparent-diffusion-coefficient and blood-oxygenation functional magnetic resonance imaging. Neuroimage. 2002;17:742–50. Article

  PubMed  Google Scholar  * Jin T, Kim S-G. Functional changes of apparent diffusion coefficient during visual stimulation investigated by diffusion-weighted gradient-echo fMRI. Neuroimage.

2008;41:801–12. Article  PubMed  Google Scholar  * Xu X, Wang Q, Zhong J, Zhang M. Iron deposition influences the measurement of water diffusion tensor in the human brain: a combined

analysis of diffusion and iron-induced phase changes. Neuroradiology. 2015;57:1169–78. Article  PubMed  Google Scholar  * Taraku B, Woods RP, Boucher M, Espinoza R, Jog M, Al-Sharif N, et

al. Changes in white matter microstructure following serial ketamine infusions in treatment resistant depression. Hum Brain Mapp. 2023;44:2395–406. Article  PubMed  PubMed Central  Google

Scholar  * Sydnor VJ, Lyall AE, Cetin-Karayumak S, Cheung JC, Felicione JM, Akeju O, et al. Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context

of ketamine’s antidepressant effects. Transl Psychiatry. 2020;10:432. Article  CAS  PubMed  PubMed Central  Google Scholar  Download references ACKNOWLEDGEMENTS Supported by National

Institute of Mental Health Biobehavioral Research Awards for Innovative New Scientists (BRAINS) R01 grant R01MH113857 (RBP) and by the Clinical and Translational Sciences Institute at the

University of Pittsburgh (UL1-TR-001857). We are deeply grateful to the study participants for their time and dedicated collaboration in this work. We also gratefully acknowledge Chadi

Abdallah, MD, PhD, Satish Iyengar, PhD, and Lisa Parker, PhD for their assistance with this work. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * University of California San Diego School of

Medicine, San Diego, CA, USA Jared Kopelman * Carnegie Mellon University, Pittsburgh, PA, USA Timothy A. Keller * University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Benjamin

Panny, Angela Griffo, Michelle Degutis, Crystal Spotts, Nicolas Cruz, Elizabeth Bell, Kevin Do-Nguyen, Meredith L. Wallace, Robert H. Howland & Rebecca B. Price * Baylor College of

Medicine and Michael E. DeBakey VA Medical Center, Houston, TX, USA Sanjay J. Mathew Authors * Jared Kopelman View author publications You can also search for this author inPubMed Google

Scholar * Timothy A. Keller View author publications You can also search for this author inPubMed Google Scholar * Benjamin Panny View author publications You can also search for this author

inPubMed Google Scholar * Angela Griffo View author publications You can also search for this author inPubMed Google Scholar * Michelle Degutis View author publications You can also search

for this author inPubMed Google Scholar * Crystal Spotts View author publications You can also search for this author inPubMed Google Scholar * Nicolas Cruz View author publications You can

also search for this author inPubMed Google Scholar * Elizabeth Bell View author publications You can also search for this author inPubMed Google Scholar * Kevin Do-Nguyen View author

publications You can also search for this author inPubMed Google Scholar * Meredith L. Wallace View author publications You can also search for this author inPubMed Google Scholar * Sanjay

J. Mathew View author publications You can also search for this author inPubMed Google Scholar * Robert H. Howland View author publications You can also search for this author inPubMed 

Google Scholar * Rebecca B. Price View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS TAK, MLW, SJM, and RBP contributed to the concept and

design of the study. BP, AG, MD, CS, NC, KD-N, EB, RHH, and RBP contributed to the acquisition of the data. JK and RBP analyzed the data. JK drafted the manuscript and all authors provided

substantive revisions. CORRESPONDING AUTHOR Correspondence to Rebecca B. Price. ETHICS DECLARATIONS COMPETING INTERESTS RBP is the named inventor on a University of Pittsburgh-owned patent

filing related to a novel combination intervention tested in this clinical trial. SJM is supported through the use of facilities and resources at the Michael E. DeBakey VA Medical Center,

Houston, Texas, and receives support from The Menninger Clinic. SJM has served as a consultant to Alkermes, Allergan, Axsome Therapeutics, BioXcel Therapeutics, Clexio Biosciences, Eleusis,

EMA Wellness, Engrail Therapeutics, Greenwich Biosciences, Intra-Cellular Therapies, Janssen, Levo Therapeutics, Neurocrine, Perception Neuroscience, Praxis Precision Medicines, Relmada

Therapeutics, Sage Therapeutics, Seelos Therapeutics, Sunovion, and Signant Health. He has received research support from Biohaven Pharmaceuticals, Merck, Neurocrine, Sage Therapeutics, and

VistaGen Therapeutics. All other authors report no financial conflicts of interest to disclose. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to

jurisdictional claims in published maps and institutional affiliations. SUPPLEMENTARY INFORMATION ONLINE SUPPLEMENT RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a

Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit

to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are

included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and

your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this

license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Kopelman, J., Keller, T.A., Panny, B. _et al._ Rapid neuroplasticity

changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression. _Transl Psychiatry_ 13, 159 (2023). https://doi.org/10.1038/s41398-023-02451-0

Download citation * Received: 25 March 2023 * Revised: 17 April 2023 * Accepted: 25 April 2023 * Published: 09 May 2023 * DOI: https://doi.org/10.1038/s41398-023-02451-0 SHARE THIS ARTICLE

Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided

by the Springer Nature SharedIt content-sharing initiative